# A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer

> **NCT02721641** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 69 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Herceptin

## Key facts

- **NCT ID:** NCT02721641
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2017-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02721641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02721641, "A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02721641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*